Theorem Clinical Research

R&D Trends

European Union to boost Ebola research with $30.9 million

Thursday, October 23, 2014 01:17 PM

The European Commission (E.C.) has announced $30.9 million from the European Union (E.U.) budget for urgently needed Ebola research. The funding will go to five projects, ranging from a large-scale clinical trial of a potential vaccine, to testing existing and novel compounds to treat Ebola. The money from Horizon 2020, an E.U. research and innovation program, will be provided via a fast-track procedure in order to start work as soon as possible. The commission also is working with industry on the further development of vaccines, drugs and diagnostics for Ebola and other haemorrhagic diseases within the Innovative Medicines Initiative.

More... »


ALS ACT, ALS Association, Northeast ALS Consortium request proposals

Thursday, October 23, 2014 01:12 PM

ALS ACT, a novel academic-foundation-industry partnership; the ALS Association, a Wash. D.C.-based national nonprofit organization; and the translational Northeast ALS Consortium (NEALS) clinical trials network have announced a call for phase II clinical trial applications for novel, high-potential treatments in amyotrophic lateral sclerosis (ALS).

More... »


Profectus BioSciences receives Army funding for Ebola, Marburg viruses

Thursday, October 23, 2014 01:06 PM

Profectus BioSciences, a Baltimore, Md.-based clinical-stage vaccine company, and the Galveston National Laboratory (GNL) at the University of Texas Medical Branch at Galveston (UTMB) have received a three-year $8.5 million grant from the U.S. Army. The grant will support studies directed at early steps of the ongoing development of a vaccine to provide pre- and post-exposure protection against exposure with all major strains of Ebola and Marburg viruses.

More... »

Johnson & Johnson to speed Ebola vaccine development, expand production

Thursday, October 23, 2014 01:03 PM

Johnson & Johnson has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program in development at Janssen Pharmaceutical Companies. The company is closely collaborating with the World Health Organization (WHO), the National Institute of Allergy and Infectious Diseases (NIAID), as well as other key stakeholders, governments and public health authorities on the clinical testing, development, production and distribution of the vaccine regimen.

More... »

Cancer Research U.K. launches $16M biotherapeutics funding scheme

Wednesday, October 22, 2014 11:43 AM

Cancer Research U.K. has launched a new biotherapeutics funding schemes to give new opportunities to scientists and clinicians to harness the power of biotherapeutic treatments. Applications for the award will be judged on the potential of turning the research findings into new preventative, diagnostic or therapeutic approaches for cancer.

More... »

SBRI Healthcare launches $4M competition

Wednesday, October 22, 2014 11:41 AM

Small Business Research Initiative (SBRI) Healthcare, an NHS England funded initiative to develop innovative products that address unmet health needs, has launched the latest SBRI Healthcare competition, which aims to accelerate development and NHS adoption of new technologies. In the second tranche of funding this year, a further $4 million is on offer to companies working in priority healthcare areas, including brain injury; child and adolescent mental health; diabetic foot ulcers; imaging; and outpatient services.

More... »

Inovio Pharmaceuticals, MedImmune, University of Pennsylvania partner

Wednesday, October 22, 2014 11:39 AM

The Defense Advanced Research Projects Agency (DARPA) has awarded $12.2 million for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of PennsylvaniaInovio Pharmaceuticals and MedImmune, the global biologics R&D arm of AstraZeneca. The group will develop DNA-based monoclonal antibodies (mAbs) for infectious disease treatment. DARPA is an agency of the U.S. Department of Defense that creates and supports novel technologies important for national security.

More... »

National Alzheimer's Plan milestones must be strengthened to meet 2025 goal

Wednesday, October 22, 2014 11:33 AM

The U.S. government has initiated a major effort to prevent and effectively treat Alzheimer's disease by 2025. However, a workgroup of nearly 40 Alzheimer's researchers and scientists said the research milestones in the U.S. government's National Plan to Address Alzheimer's Disease must be broadened in scope, increased in scale and adequately funded in order to successfully achieve this goal. A series of proposals by the workgroup to enlarge and strengthen the plan have been published in Alzheimer's & Dementia: the Journal of the Alzheimer's Association.

More... »

Physicians to pharmas: provide patient services or face irrelevance

Friday, October 17, 2014 02:49 PM

Physicians are looking to pharmaceutical companies to help them keep patients engaged in their healthcare by providing patient services, according to the ePharma Physician 2014 study from Manhattan Research, part of Burlington, Mass.-based Decision Resources Group.

More... »

Cardiorentis, Roche collaborate on Ularitide

Friday, October 17, 2014 12:49 PM

Cardiorentis, a Switzerland-based, privately held biopharmaceutical company, is collaborating with Roche to establish the therapeutic efficacy and safety of Ularitide, the company's investigational drug for acute heart failure (AHF). Cardiorentis will incorporate Roche's advanced in vitro diagnostic tests into its TRUE-AHF phase III study to characterize the pharmacological properties of Ularitide, evaluate its benefit-risk profile and the appropriate clinical application in patients.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs